Exfoliative cheilitis is an inflammatory condition that can significantly impair quality of life. This is the first reported case of an interleukin-23 inhibitor, tildrakizumab, for the treatment of a chronic, refractory case of exfoliative cheilitis.
Primary Language | English |
---|---|
Subjects | Clinical Sciences |
Journal Section | Letter to Editor |
Authors | |
Publication Date | January 31, 2023 |
Published in Issue | Year 2023 Volume: 6 Issue: 1 |